Julie Gentil

Julie Gentil

Auto-generated profile, based on publicly available information

Julie Gentil

Breast and Gynaecologic Cancer Registry of Cote d’Or, Centre Georges François Leclerc, 1 rue Professeur Marion BP 77980, Dijon Cedex, 21079, France

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JGJulie Gentil
Julie Gentil
TDTienhan Sandrine Dabakuyo-Yonli
Tienhan Sandrine Dabakuyo-Yonli
SOSamiratou Ouedraogo
Samiratou Ouedraogo
MPMarie-Laure Poillot
Marie-Laure Poillot
ODOlivier Dejardin
Olivier Dejardin
PAPatrick Arveux
Patrick Arveux
It has been shown in several studies that survival in cancer patients who were operated on by a high-volume surgeon was better. Why then do all patients not benefit from treatment by these experienced surgeons? The aim of our work was to study the hypothesis that in breast cancer, geographical isolation and the socio-economic level have an impact on the likelihood of being treated by a specialized breast-cancer surgeon.

15 October 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PDPegdwende Olivia Dialla
Pegdwende Olivia Dialla
TDTienhan Sandrine Dabakuyo-Yonli
Tienhan Sandrine Dabakuyo-Yonli
SMSophie Marilier
Sophie Marilier
JGJulie Gentil
Julie Gentil
PRPatrick Roignot
Patrick Roignot
PAPatrick Arveux
Patrick Arveux
Background: A large proportion of women with breast cancer (BC) are elderly. However, there is a lack of information regarding BC prognostic factors and care in this population. The aims of this study were to assess the prognostic factors of relative survival (RS) among women with BC aged ≥ 75 years old and to identify the predictive factors of treatments administered to this population. Methods: A population-based study was performed using data from the Cote d’Or breast and gynaecological cancer registry. Women aged 75 years and older with primary invasive BC and resident in Cote d’Or at the time of diagnosis made between January 1998 and December 2008 were retrospectively selected. Prognostic factors of RS were estimated in a generalized linear model with a Poisson error structure. RS rate for the whole population was given at 5 years. Logistic regression models were used to identify the predictors of the treatments administered. Results: Six hundred and eighty-one women were included. Median age at diagnosis was 80. Comorbidities (p=0.02), pT stage (p=0.04), metastases (p=<0.001), having a family doctor (p=0.03) and hormone-receptor status (p=0.006) were independent prognostic factors of RS. The RS rate at 5 years for the whole population was 78.2%, 95%CI = [72.2-83.0]. Age, pT stage, metastases, histoprognostic SBR grade, hormone receptor status and comorbidities were frequently found to be predictors of treatment with surgery alone, hormone therapy alone, breast conserving surgery plus adjuvant therapy and mastectomy plus adjuvant therapy. Conclusions: Comorbid conditions adversely affect survival in older women with breast cancer. Moreover the results of this study showed that there are numerous predictors of the type of treatment administered, and that the most important were age and comorbidities.

10 November 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZHZeinab Hamidou
Zeinab Hamidou
SCSylvain Causeret
Sylvain Causeret
TDTienhan Sandrine Dabakuyo-Yonli
Tienhan Sandrine Dabakuyo-Yonli
JGJulie Gentil
Julie Gentil
LALaurent Arnould
Laurent Arnould
PAPatrick Arveux
Patrick Arveux
Background: The aim of this population-based study was to assess independent prognostic factors in ovarian cancer using relative survival (RS) and to investigate changes in RS rates from 1982 to 2005. Methods: Data on 748 patients with ovarian cancer were provided by the Côte d'Or gynaecologic cancer registry. The RS was estimated using a generalized linear model with a Poisson error structure. Relative survival and its 95% confidence interval (CI) were described at the following specific time points 1, 3 and 5 years. The effect of prognostic factors on survival was assessed with multivariate analyses of RS. Results: The median follow-up was 12 years. The RS rates at 1, 3 and 5 years were 81%, 55% and 44%, respectively. As compared with the period 1982-1989, an improvement in survival was found for the period 1998-2005: HR = 0.52[0.40-0.67]. Women who lived in urban areas had better RS: HR = 0.82[0.67-0.99]. Patients with epithelial types of ovarian cancer other than mucinous or endometrioid cancer had worse RS than those with serous histology. Age ≥ 70 years was associated with lower survival. Conclusions: Period of diagnosis, stage at diagnosis, histology, place of residence and age were independent prognostic factors for survival in ovarian cancer. An improvement in the survival rate was observed after 1998 but a significant improvement was limited to advanced stage cancers.